🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsEnergy expenditure increase from GCG component — November 2025

Energy expenditure increase from GCG component — November 2025

amsterdam_pete Thu, Mar 5, 2026 at 9:49 AM 10 replies 790 viewsPage 1 of 2
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Mar 5, 2026 at 9:49 AM#1

Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does not support as firmly as people think.

For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

What I am after is why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose.

Happy to be told the question itself is wrong.

29 24JakeSmashed95, NauseaFreeNow, SteveThurs and 26 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Mar 5, 2026 at 11:03 AM#2

Taking the question as asked, rather than the general version of it. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Last edited: Mar 5, 2026 at 4:03 PM
28 23VendorMark, COA_Karl, MikeFit_NJ and 25 others
Reply Quote Save Share Report
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Mar 5, 2026 at 12:17 PM#3
Dr.GastroMayo said:
The mechanism and the magnitude are separate questions.

Dr.GastroMayo has the substance of this right. The condition it depends on is worth stating. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.

27 22robert_kc, dan_philly, MeganSA_TX and 24 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Mar 5, 2026 at 1:31 PM#4
amsterdam_pete said:
Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does…

Adding a me-too, because a thread of one person's experience is not much use. I had assumed I was the exception until I read this.

26 21rachel_ABQ, traveltech_sara, AttorneyGrant and 23 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Mar 5, 2026 at 8:37 PM#5

Clinical perspective, offered as context rather than as advice. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

25 20sarah_nash92, FitDadDave, RunnerRach and 22 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register